Loading...
DF2726A, a new IL-8 signalling inhibitor, is able to counteract chemotherapy-induced neuropathic pain
Brandolini, L Castelli, V Aramini, A Giorgio, C Bianchini, G Russo, R De Caro, C D’angelo, M Catanesi, M Benedetti, E
Brandolini, L
Castelli, V
Aramini, A
Giorgio, C
Bianchini, G
Russo, R
De Caro, C
D’angelo, M
Catanesi, M
Benedetti, E
Citations
Altmetric:
Genre
Journal Article
Date
2019-12-01
Advisor
Committee member
Group
Department
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
10.1038/s41598-019-48231-z
Abstract
© 2019, The Author(s). Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect of several anti-neoplastics and a main cause of sensory disturbances in cancer survivors, negatively impacting patients’ quality of life. Peripheral nerve degeneration or small fibre neuropathy is generally accepted as the underlying mechanism in the development of CIPN. Recent evidence has contributed to clarify the determinant role of cytokines and chemokines in the process leading to neuronal hyperexcitability. Exposure to oxaliplatin triggers alterations in peripheral neuropathic pathways previously linked to IL-8 pathway. We investigated a novel selective inhibitor of IL-8 receptors, DF2726A, and showed its effects in counteracting CINP pathways, extending the relevance of the activation of IL-8 pathway to the class of platinum chemotherapeutics. Based on our results, we suggest that DF2726A might be a promising candidate for clinical treatment of CIPN conditions due to its efficacy and optimized pharmacokinetic/pharmacodynamic profile.
Description
Citation
Citation to related work
Springer Science and Business Media LLC
Has part
Scientific Reports
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu